The Use of Topical Calcineurin Inhibitors in Atopic Dermatitis
Annie Crissinger1, Nicholas V. Nguyen*, 2
Identifiers and Pagination:Year: 2014
First Page: 12
Last Page: 17
Publisher Id: TODJ-8-12
Article History:Received Date: 7/02/2014
Revision Received Date: 26/03/2014
Acceptance Date: 26/02/2014
Electronic publication date: 18/4/2014
Collection year: 2014
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In recent years, two topical calcineurin inhibitors have emerged as effective alternatives to corticosteroids for the treatment of atopic dermatitis. Decisions regarding first line therapy between pimecrolimus and tacrolimus are often based on anecdotal evidence. Herein, we review the current evidence supporting the use of pimecrolimus and tacrolimus in atopic dermatitis as well as key differences in safety, tolerability, and cost between the drugs.